Gloom Is Overblown: Allergy Vaccine Sector Is Poised To Globalize
The failure of Circassia’s cat allergy vaccine product in a Phase III study, and other recent setbacks including a one-year delay to Allergy Therapeutics’ US ambitions, have not stymied the excitement in a sector that promises new approaches to grass, tree, peanut and other food allergies, and much more convenient treatment regimens.
You may also be interested in...
Merck & Co has returned all US marketing rights to ALK-Abello’s sublingual allergy tablets to the Danish company, casting a pall over the sector that has this year been dismayed by late-stage failures of new products and delays in drug development.
The UK biotech’s potential revolutionary approach to allergies has failed to achieve its primary endpoint in a Phase III study, halting much of its research in the allergy area and casting a shadow over UK innovation.
Merck & Co has submitted a BLA for what is likely to be its third sublingual allergy immunotherapy (SLIT) tablet to become available in the US, one developed to treat house dust mite (HDM) allergies, an important cause of allergic rhinitis and allergic asthma that might boost so-far underwhelming US sales of its new allergy products.